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In 2010, national guidelines recommended that women with non-
metastatic, hormone receptor–positive breast cancer take adjuvant
hormone therapy for 5 years. As results from randomized clinical
trials became available, guidelines were revised in 2014 to recom-
mend 10 years of therapy. Despite evidence of its efficacy, low
initiation rates have been documented among women insured by
New York State Medicaid. This article describes a coordinated
quality improvement pilot  conducted by a state  department  of
health and Medicaid managed care plans to engage women in
guideline-concordant adjuvant hormone therapy.
Methods
Women enrolled in Medicaid managed care with nonmetastatic,
hormone receptor–positive breast  cancer and who had surgery
from May 1, 2012, through November 30, 2012, were identified
using linked Medicaid and Cancer Registry data. Adjuvant hor-
mone therapy status was determined from Medicaid pharmacy
data. Contact information for nonadherent women was supplied to
health plan care managers who conducted outreach activities. Ad-
juvant hormone therapy status in the 6 months following outreach
was evaluated.
Results
In the 6 months postoutreach, 61% of women in the contacted
group filled at least 1 prescription, compared with 52% in the non-
contacted group. Among those with at least 1 filled prescription,
50% of the contacted group were adherent, compared with 25% in
the noncontacted group.
Conclusion
This pilot suggests outreach conducted by health plan care man-
agers, facilitated by linked Medicaid and Cancer Registry data, is
an effective method to improve adjuvant hormone therapy initi-
ation and adherence rates in Medicaid managed care–insured wo-
men.
Introduction
Breast cancer is the most commonly diagnosed cancer in women
in the United States and has the second highest death rate (1–5). In
2013 in New York State (NYS), 15,680 women were diagnosed
with breast cancer, and 2,576 died (6). Roughly 70% of breast
cancers are hormone receptor positive (HR-positive) (ie, the tu-
mor’s growth is  promoted by estrogen,  progesterone,  or  both)
(7,8). Adjuvant hormone therapy (AHT) works either by lowering
hormone levels or blocking the action of hormone on tumor cells,
and it reduces annual recurrence rates by approximately 40% as
well as improves survival rates (9–11). Because results from ran-
domized clinical trials demonstrate additional benefits from longer
courses of treatment, national guidelines in 2014 recommended
extending the use of AHT for women with nonmetastatic, HR-pos-
itive  breast  cancer  from  the  previously  recommended  2010
guideline of 5 years to 10 years, starting within a year of diagnos-
is (12). Despite this change in recommendation, suboptimal use of
AHT is documented, particularly among low-income, minority,
and young women (13–18).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health
and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2016/16_0185.htm • Centers for Disease Control and Prevention      1
NYS has one of the largest Medicaid programs in the country,
serving a low-income, largely minority population. In 2013, more
than 5.3 million New Yorkers were insured by Medicaid (19). Pre-
vious investigation into AHT use in NYS’s Medicaid population
indicated that just 68% of women diagnosed from 2004 through
2006 initiated AHT within 1 year of diagnosis, and 58% of wo-
men who initiated AHT were adherent in the following year (20).
These  findings  are  consistent  with  those  of  previous  studies
(13,21).
Given the need to improve AHT use by NYS Medicaid-insured
women and the ability to identify those who are not receiving
AHT by linking their Medicaid data with NYS Cancer Registry
(NYSCR) data, the NYS Department of Health implemented a
quality improvement pilot. This article describes the coordinated,




NYS Medicaid encounter data (ie, health service use data submit-
ted by managed care plans) as well as Medicaid claim and eligibil-
ity data were used to identify women aged 21 to 64 years with a
breast  cancer  surgery  (captured  using breast  cancer  diagnosis
codes  in  conjunction  with  surgical  procedure  codes)  in  the  7
month period from May through November 2012. Because this pi-
lot was designed to target women with newly diagnosed breast
cancer, women with a breast cancer surgery in the preceding 5
years were eliminated from the cohort. Medicaid data on breast
cancer surgery were then linked to NYSCR data to confirm the
breast cancer diagnosis and to extract information on stage of dis-
ease (local, regional, or metastatic) and tumor HR status. The co-
hort was further restricted to exclude women who were also Medi-
care beneficiaries (called “dual-eligibles”) because Medicare phar-
macy data were not available. The final cohort comprised women
with nonmetastatic, HR-positive breast cancer who were enrolled
in one of 8 Medicaid managed care (MMC) plans that volunteered
to participate in the pilot. This cohort represented approximately
half (8 of 17) of the mainstream MMC plans in NYS and covered
all regions of the state.
NYS Medicaid pharmacy encounter data were used to determine
AHT status. Women captured in 1 of the following 3 groups were
considered eligible for outreach: AHT noninitiated, women with
no filled AHT prescriptions from April 2012 through the date of
the data pull (August 7, 2013); AHT nonadherent, women with a
medication possession ratio of less than 0.8 (sum of days’ supply
divided by the difference between last and first fill dates); and
AHT discontinued, women with no filled prescriptions from April
2013 through the data pull. We also stratified data according to
race/ethnicity (white, Hispanic, black, Asian/Pacific Islander, or
Native American/other/unknown) and region of residence (New
York City or elsewhere in NYS).
Outreach
Written outreach materials were developed collaboratively with
health plans and available to care managers in both English and
Spanish (Appendix). Before commencing telephone outreach to
patients, health plans sent letters to patients’ physicians (prefer-
ably oncologists if one was identified in encounter data). Physi-
cian letters had a dual-purpose; they were sent as a courtesy to no-
tify physicians that the health plans would be contacting their pa-
tients, and they also requested that physicians contact health plan
staff if a patient should not be called because of extenuating cir-
cumstances. After the physician letters were sent, health plans sent
letters to patients informing them that a representative from the
health plan would be calling to discuss their recent treatment for
breast cancer. Health plan care managers made up to 5 attempts to
contact each patient by telephone. To guide their conversation
with  patients,  care  managers  used  a  telephone  script  that  ad-
dressed current guidelines for AHT use, provided assurance that
the cost of AHT was covered by health plans, and offered to help
women talk with their doctors about AHT.
To facilitate outreach, the following information was extracted
from Medicaid data systems and supplied to health plans: patient
name, address, telephone number, date of birth, and AHT status;
oncologists’ National Provider Identifier code; and an indicator to
identify Spanish-speaking women. A web-based data exchange
platform was used to securely transfer data to health plan staff and
collect information on contact attempts, including outreach com-
pletion status and date.
For the analyses, we defined 3 groups: 1) women who met our in-
clusion criteria but who were AHT adherent at the start of activit-
ies, 2) women who were contacted and completed the telephone
script with care managers, and 3) women whom care managers
were unable to contact or who refused to complete all components
of the telephone script.
Ideally, the evaluation period would commence on the date that
outreach was completed; however, because of variation in health
plan roll-out of pilot activities and challenges contacting women,
outreach  completion  dates  ranged  from  September  through
November 2013. Additionally,  although health plan care man-
agers submitted outreach completion dates via the web-based data
exchange platform for women contacted by telephone, a similar
intervention start date was not available for the 2 control groups
(those  who  were  AHT  adherent  and  those  who  were  not
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contacted). To compare the 3 groups, the median outreach comple-
tion date (September 25, 2013) was used as the standard start date
for evaluating AHT outcomes for all 3 groups. To validate our res-
ults, we compared 2 sets of analyses, 1 using the actual outreach
completion date and the other using the median outreach comple-
tion date. Results were the same (data not shown), suggesting that
this was an appropriate approach.
Outcome assessment and statistical analysis
NYS Medicaid data were used to identify AHT prescriptions filled
within 6 months of the median outreach completion date. The pro-
portion of women with at least 1 filled AHT prescription after
September 25, 2013, was calculated. The AHT possession ratio
was also calculated as the sum of days’ supply of AHT prescrip-
tions from September 25, 2013, through March 23, 2014, divided
by 180. Women were considered AHT adherent if the AHT pos-
session ratio was greater than or equal to 0.8.
Fisher’s  exact  and χ2  tests  were used to assess significance in
demographic distributions between contacted and noncontacted
groups. One-tailed t tests and 1-tailed Fisher’s exact tests were
used to determine significant differences in AHT use postinterven-
tion. Analyses were performed using SAS 9.4 and SAS Enterprise
Guide 6.1 (SAS Institute, Inc). Significance was set at P < .05.
This project was granted exempt status by the New York State De-
partment of Health’s institutional review board.
Results
A total of 1,614 women who had breast cancer surgery from May
1, 2012, through November 30, 2012, were identified. Among
these women, 255 were aged 21 to 64 years, were not dual-eli-
gible, had been diagnosed with nonmetastatic, HR-positive breast
cancer, and were enrolled in a participating health plan as of July
2013.  Within this  cohort,  81 (32%) women required outreach;
their AHT status before outreach was as follows: 46 (57%) were
AHT noninitiated,  19  (23%)  were  AHT nonadherent,  and  16
(20%) were AHT discontinued. The remaining 174 women (68%)
were AHT adherent and were not targeted for outreach.
Of the 81 women identified for outreach, 3 (4%) women were dis-
enrolled from MMC between the release of data and the start of
outreach activities, 42 (52%) were successfully contacted by tele-
phone, and 36 (44%) could not be reached by telephone or did not
complete the telephone script. As of March 2014, 163 (94%) of
the AHT adherent group, 31 (86%) of the noncontacted group, and
36 (86%) women contacted were still enrolled in NYS MMC as
non–dual-eligible.
Race/ethnicity proportions did not differ significantly (P = .87),
with more than one-third of the women in each group white (Ta-
ble 1). Among women in the contacted group, 47% were aged 50
to  64  years,  whereas  68%  were  in  the  noncontacted  group;
however, the difference was not significant (P = .16). Most wo-
men in both groups resided in New York City (P = .89). No differ-
ence in proportion between the groups was noted with respect to
stage of disease; most women in both groups had localized breast
cancer (P = .89). The AHT adherent group served as a positive
control for the adherence after the outreach, and data for this group
are also presented (Table 1).
Among patients who were successfully contacted, 22 of 36 (61%)
initiated AHT within 6 months of outreach (Table 2). This num-
ber was higher than for the group not successfully contacted; only
16 of 31 patients (52%) had initiated AHT. Among those with at
least 1 filled AHT prescription, the contacted group had an aver-
age of 4.4 AHT prescriptions filled during the 6-month follow-up
period, compared with 3.4 in the unable-to-contact group (data not
shown).  Although  the  adherence  rate  for  the  contacted  group
(50%) was not as high as that for the AHT adherent group (86%),
it was higher than that for the nonadherent/noncontacted group
(25%). Outreach status was marginally associated with adherence
after outreach (P = .11).
We also compared the adherence rates in different subgroups (Ta-
ble 3). Among women with a preoutreach status of AHT noniniti-
ated who were contacted, 60% were adherent after outreach, com-
pared with 37% in the noncontacted group. Higher adherence rates
were observed among white, black and Asian/Pacific Islander wo-
men, as well as across all strata of age, region of residence, cancer
stage, and preoutreach status.
Discussion
Nearly one third (32%) of MMC-insured women with nonmeta-
static, HR-positive breast cancer were not AHT adherent and met
our eligibility criteria. Results of the pilot suggest a benefit from
health plan outreach, because women who were contacted were
more likely to initiate and adhere to AHT, although the differ-
ences were not significant. Subpopulations such as white, black
and Asian/Pacific Islander, as well as all strata of age group, re-
gion of residence, cancer stage and preoutreach status showed im-
provement in AHT adherence in the contacted group compared
with the noncontacted group, suggesting that the outreach may be
effective for diverse demographic groups. Among all races/ethni-
cities, Native American/other/unknown women had a high adher-
ence  rate  before  outreach  (77.8%),  as  did  Hispanic  women
(77.1%) (Table 1). These rates are comparable with rates reported
in the literature of 70% to 85% (15,21–24). However, white and
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black women lagged behind with preoutreach AHT adherence
rates of 60.7% and 65.2%, respectively. Given the observed dis-
parities within our cohort of MMC-insured women, it makes sense
that  the  greatest  gains  made by  our  outreach  were  among the
groups with the lowest AHT adherence at baseline.
Our study has limitations. Medicaid pharmacy data indicate that a
prescription was filled and picked up by the patient; it does not,
however,  indicate  that  the patient  took the medication as  pre-
scribed. Also, this was a small-scale pilot, in which half of MMC
plans participated. As such, the number of women included in the
pilot and available for analysis was small. Because of our small
study  population,  what  appear  to  be  meaningful  differences
between groups were not statistically significant. We did not con-
duct a randomized control trial; our testing and negative control
groups were categorized on the basis of whether we could success-
fully contact them, which may have introduced bias between the 2
groups.
Although the number of  breast  cancers  diagnosed in the NYS
Medicaid population is small, this project (by encouraging MMC-
insured women to initiate and adhere to AHT) has the potential to
prevent cancer recurrence and save lives. For these reasons and
based on the initial, positive findings presented here — in addi-
tion to  the  low cost  of  the  project  — the NYS Department  of
Health is moving forward to implement this pilot statewide in all
mainstream MMC plans. Additionally, as NYS moves to develop
an all-payer database (APD), the information contained within the
APD would allow this project to expand and include Medicare and
commercially insured women.
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Tables
Table 1. Characteristics of Women in a Pilot Study to Improve Adjuvant Hormone Therapy Use Among Those With Breast Cancera, by Cohort, 8 Medicaid Managed
Care Health Plans in New York State, 2012–2014
Characteristic
Study Cohort
Total No. (N =
230) P Valueb
AHT Adherent (n = 163)
AHT Nonadherent
Contacted (n = 36) Not Contacted (n = 31)
No. (%)
Race/ethnicity
White 37 (23) 13 (36) 11 (35) 61
.87c
Hispanic 54 (33) 9 (25) 7 (23) 70
Black 30 (18) 9 (25) 7 (23) 46
Asian/Pacific Islander 28 (17) 4 (11) 3 (10) 35
Native American/other/unknown 14 (9) 1 (3) 3 (10) 18
Age group, y
50–64 95 (58) 17 (47) 21 (68) 133
.16d40–49 53 (33) 13 (36) 5 (16) 71
21–39 15 (9) 6 (17) 5 (16) 26
Region of residence
New York City 123 (75) 25 (69) 22 (71) 170
.89d
Elsewhere in New York State 40 (25) 11 (31) 9 (29) 60
Cancer stage
Local 105 (64) 25 (69) 22 (71) 152
.89d
Regional 58 (36) 11 (31) 9 (29) 78
Abbreviation: AHT, adjuvant hormone therapy.
a Women who were not dually eligible for Medicare, who were aged 21 to 64 years with diagnosed nonmetastatic hormone receptor–positive breast cancer, and
who had breast cancer surgery from May 1, 2012, through November 30, 2012.
b Compares distribution in the noncontacted and contacted groups.
c Calculating using Fisher’s exact test.
d Calculating using χ2 test.
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Table 2. AHT Initiation and Adherence 6 Months Postoutreach, by Cohort, Pilot Study to Improve AHT Use by Women With Breast Cancer in 8 New York State Medi-
caid Managed Care Health Plans, 2014
Characteristic
Study Cohort
Total No. P ValueaAHT Adherent
AHT Nonadherent/
Contacted Not Contacted
At least 1 filled AHT prescription post-September 25, 2013
Yes, no. (%) 156 (96) 22 (61) 16 (52) 194
.20b
No, no. (%) 7 (4) 14 (39) 15 (48) 36
Total no. 163 36 31 230  —
AHT adherentc postoutreach
Yes, no. (%) 134 (86) 11 (50) 4 (25) 149
.11d
No, no. (%) 22 (14) 11 (50) 12 (75) 45
Total no. 156 22 16 194  —
Abbreviations: — , not applicable; AHT, adjuvant hormone therapy.
a Compares adherence rates of the noncontacted and contacted groups.
b Calculated using χ2 test.
c Data limited to women with at least 1 filled AHT prescription post-September 25, 2013.
d Calculated using Fisher’s exact test.
PREVENTING CHRONIC DISEASE VOLUME 13, E120
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY SEPTEMBER 2016
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2016/16_0185.htm • Centers for Disease Control and Prevention       7
Table 3. Comparison of Adherence Rates Postoutreach, by Selected Demographics and Cohort, Among Women With at Least 1 Filled AHT Prescription Post-








White 29 (83) 6 (75) 1 (14)
Hispanic 48 (91) 1 (17) 2 (50)
Black 24 (83) 3 (43) 0
Asian/Pacific Islander 22 (81) 1 (100) 1 (50)
Native American/other/unknown 11 (92) 0 0
Age group, y
50–64 79 (87) 5 (50) 3 (30)
40–49 42 (84) 4 (44) 1 (33)
21–39 13 (87) 2 (67) 0
Region of residence
New York City 102 (86) 8 (53) 3 (25)
Elsewhere in New York State 32 (87) 3 (43) 1 (25)
Cancer stage
Local 92 (90) 5 (36) 2 (18)
Regional 42 (78) 6 (75) 2 (40)
Preoutreach status
AHT noninitiated 0 6 (60) 3 (37)
AHT discontinued 0 3 (50) 0
AHT nonadherent 0 2 (33) 1 (14)
Total 134 (86) 11 (50) 4 (25)
Abbreviation: AHT, adjuvant hormone therapy.
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Appendix. Outreach Materials Used in the Pilot.
This file is available for download as a Microsoft Word document [DOCX-70KB] at
https://www.cdc.gov/pcd/issues/2016/docs/16_0185_Appendix.docx
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